Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Iressa User Fee Date Pushed To May; Will Advisory Cmte. Take Second Look?

Executive Summary

FDA will take regulatory action on AstraZeneca's Iressa (gefitinib) by May 5
Advertisement

Related Content

Iressa Clears FDA: Phase IV Symptom Trial Will Be First Shot At Full Approval
Iressa Postmarketing Trial Modeled On Tarceva Phase III Under Consideration
“Optimal” Dose Finding Could Result In More Late-Stage Drug Success
Genentech/OSI Tarceva Lung Cancer Trial Modified Following “Safety Signal”
Iressa Approval Would Set Bad Precedent For Oncology, Genta CEO Tells BIO
Tidbits From The Fourth Quarter Calls, In Brief
Oncologic Accelerated Approval Phase IV Studies For 7 Drugs To Be Reviewed
FDA Accelerated Approval Review Asks If Reg Gives De Facto Exclusivity
Accelerated Approval, Arava, Factive Are Topics For Early 2003 Committees
AstraZeneca Iressa NDA Review Complicated By Pneumonia Reports
Advertisement
UsernamePublicRestriction

Register

PS041090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel